GW Pharmaceuticals
Cannabidiol drug found to aid in devastating childhood epilepsy condition
May 25, 2017Research and Development GW Pharmaceuticals, cannabidoil, epilepsy
A treatment derived from cannabis has been found to produce remarkable results in children who have epilepsy. Cannabidoil, when offered …
GW Pharma releases positive data on cannabidiol-based Phase III trial
September 28, 2016Research and Development Epidiolex, GW Pharmaceuticals, Marijuana, Medical marijuana, cannabis
GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published …
Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…
July 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics
Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …
GW Pharmaceuticals says Phase III trials for Epidiolex to treat rare epilepsy in children shows positive results
June 27, 2016Research and Development, Sales and Marketing Epidiolex, GW Pharmaceuticals, NDA, US FDA, drug trial, orphan drug
GW Pharmaceuticals (Nasdaq: GWPH) said late-stage trials for its Epidiolex (cannabidiol or CBD) to treat Lennox-Gastaut syndrome (LGS), a rare …
GW Pharma starts Phase III trials for Tuberous Sclerosis Complex drug
April 11, 2016Research and Development Epidiolex, GW Pharmaceuticals, Tuberous Sclerosis Complex, genetics, rare disease
GW Pharmaceuticals Plc (Nasdaq: GWPH) said it has started late-stage trials for its Epidiolex (cannabidiol or CBD) to treat seizures …
GW Pharma appoints president and moves CEO to US
May 22, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GW Pharmaceuticals, Julian Gangolli
US biopharma firm GW Pharmaceuticals has appointed Julian Gangolli as president of its North American division, and is also relocating its …
GW Pharmaceuticals hires chief operating officer
October 4, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Chris Tovey, GW Pharmaceuticals
GW Pharmaceuticals has announced the appointment of Christopher John Tovey to the newly created position of chief operating officer. Tovey, …
Bayer launches world’s first cannabis-derived prescription drug
June 21, 2010Sales and Marketing Bayer, GW Pharmaceuticals, Sativex
Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK. Sativex treats the spasticity symptoms of multiple …
Cannabis-derived MS treatment filed in Europe
September 5, 2006Sales and Marketing GW Pharmaceuticals, Sativex
Sativex, the cannabis-derived product developed by GW Pharmaceuticals could be finally set for approval after a delay of around two …
Patient demand brings Sativex to UK ahead of approval
November 17, 2005Sales and Marketing GW Pharmaceuticals, Sativex
The unlicensed cannabis-based medicine Sativex will be available in the UK to treat neuropathic pain on a named patient basis …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
